{"id":60984,"date":"2025-03-25T22:02:57","date_gmt":"2025-03-25T21:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2025-03-25T22:02:57","modified_gmt":"2025-03-25T21:02:57","slug":"kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"
\n

PITTSBURGH–(BUSINESS WIRE)–KaliVir Immunotherapeutics, Inc.<\/a>, a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe presentation will focus on the company\u2019s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor.\n<\/p>\n

\nDetails on the poster presentation are below:\n<\/p>\n

\nPresentation Title:<\/b> Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI<\/b>
Abstract Number:<\/b> 484
\n
Session Date & Time:<\/b> Sunday, April 27, 2025; 2-5 pm
\n
Presenter:<\/b> Stephen Thorne, PhD, Co-founder and Chief Scientific Officer, KaliVir Immunotherapeutics\n<\/p>\n

\nAbout KaliVir Immunotherapeutics, Inc.<\/b>\n<\/p>\n

\nKaliVir Immunotherapeutics is a clinical-stage biotechnology company at the forefront of developing next-generation oncolytic immunotherapies. By harnessing the unique advantages of the vaccinia platform, KaliVir engineers optimized viral backbones to create innovative candidates for cancer treatment. The Company’s proprietary Vaccinia Enhanced Template (VET\u2122<\/sup>) platform integrates multiple genetic modifications, allowing for the systemic delivery of oncolytic vaccinia candidates and the targeted expression of therapeutic transgenes within tumors.\n<\/p>\n

\nThe Company is actively expanding its pipeline using the VET\u2122<\/sup> platform, with its capabilities validated through strategic global partnerships with Astellas Pharma and Roche. Currently, the Company has two product candidates in Phase 1 clinical trials: ASP1012, exclusively licensed and led by Astellas Pharma, and its internal lead candidate, VET3-TGI. With multiple therapeutic candidates progressing through clinical development, KaliVir is positioned as a leader in innovative cancer therapies.\n<\/p>\n

\nHeadquartered in Pittsburgh, Pennsylvania, KaliVir is committed to revolutionizing cancer treatment. For more information, visit www.kalivir.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
Lauren Arnold
\n
LA Communications
\n
Lauren@LACommunications.net<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PITTSBURGH–(BUSINESS WIRE)–KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL. The presentation will focus on the company\u2019s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60984","6":"format-standard","7":"category-industry"},"yoast_head":"\nKaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH–(BUSINESS WIRE)–KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL. The presentation will focus on the company\u2019s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T21:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting\",\"datePublished\":\"2025-03-25T21:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"wordCount\":322,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325264319\\\/en\\\/2418827\\\/22\\\/KALIVIR_BLK_RED_for_BW.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"name\":\"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325264319\\\/en\\\/2418827\\\/22\\\/KALIVIR_BLK_RED_for_BW.jpg\",\"datePublished\":\"2025-03-25T21:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325264319\\\/en\\\/2418827\\\/22\\\/KALIVIR_BLK_RED_for_BW.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325264319\\\/en\\\/2418827\\\/22\\\/KALIVIR_BLK_RED_for_BW.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","og_description":"PITTSBURGH–(BUSINESS WIRE)–KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL. The presentation will focus on the company\u2019s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-25T21:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting","datePublished":"2025-03-25T21:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"wordCount":322,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/","name":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg","datePublished":"2025-03-25T21:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250325264319\/en\/2418827\/22\/KALIVIR_BLK_RED_for_BW.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60984"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60984\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}